Objective: Xenotransplantation using pig organs could end the donor organ shortage for transplantation, but humans have xenoreactive antibodies that cause early graft rejection. Genome editing can eliminate xenoantigens in donor pigs to minimize the impact of these xenoantibodies. Here we determine whether an improved cross-match and chemical immunosuppression could result in prolonged kidney xenograft survival in a pig-to-rhesus preclinical model. Methods: Double xenoantigen (Gal and Sd a ) knockout (DKO) pigs were created using CRISPR/Cas. Serum from rhesus monkeys (n ¼ 43) was crossmatched with cells from the DKO pigs. Kidneys from the DKO pigs were transplanted into rhesus monkeys (n ¼ 6) that had the least reactive crossmatches. The rhesus recipients were immunosuppressed with anti-CD4 and anti-CD8 T-cell depletion, anti-CD154, mycophenolic acid, and steroids. Results: Rhesus antibody binding to DKO cells is reduced, but all still have positive CDC and flow cross-match. Three grafts were rejected early at 5, 6, and 6 days. Longer survival was achieved in recipients with survival to 35, 100, and 435 days. Each of the 3 early graft losses was secondary to IgM antibody-mediated rejection. The 435-day graft loss occurred secondary to IgG antibody-mediated rejection. Conclusions: Reducing xenoantigens in donor pigs and chemical immunosuppression can be used to achieve prolonged renal xenograft survival in a preclinical model, suggesting that if a negative cross-match can be obtained for humans then prolonged survival could be achieved.
Xenotransplantation using pig organs could eliminate this shortage because pigs are anatomically similar to humans, have a short gestation period (114 days), reach adult sizes quickly (3-4 months), and are amenable to genome editing. [5] [6] [7] [8] [9] [10] Xenotransplantation has not progressed to the clinic mainly because humans have preformed antibodies that bind to pig cells and cause early antibodymediated rejection (AMR), leading to graft failure. 11, 12 Initial efforts to eliminate xenoreactive antibody as a barrier to xenotransplantation focused on the development of GGTA1 knockout (KO) pigs, eliminating the xenoantigen to which 70% to 90% of xenoreactive antibodies bound. GGTA1 KO pig kidneys transplanted into non-human primates (NHPs) treated with rabbit antithymocyte globulin (RATG), tacrolimus, mycophenolic acid, and steroids, were rejected by AMR over 6 to 17 days. 13 The search for additional xenoantigens that could serve as targets for further genetic modification in donor pigs, revealed the glycan antigen Sd a to be xenoreactive for both humans and primates. 14, 15 Sd a is produced by the B4GALNT2 enzyme that is present in pigs and deleted in humans. An additional xenoantigen for humans and not primates is N-glycolylneuraminic acid, which is produced by the cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) gene.
Nuclease-based genome editing has made it possible to perform multiplex genome editing in the pig so that multiple genes can be deleted in s single reaction. 10, 21 We used CRISPR/Cas to delete 3 genes that produced enzymes responsible for the production of glycan xenoantigens-a-gal (GGTA1), N-glycolylneuraminic acid (CMAH), and Sd a antigen (B4GALNT2). CDC and flow cytometric cross-matches with TKO peripheral blood mononuclear cells (PBMC) and serum from patients on the kidney transplant waitlist showed that 50% of unsensitized patients had a negative cross-match to the TKO pig. 10, 22, 23 Recent efforts in preclinical xenotransplantation have focused on the use of pigs with GGTA1 KO and human complement regulatory transgenes (CD46/55), and thromboregulatory transgenes. [16] [17] [18] [19] Recently, we showed that GGTA1 KO/CD55 transgenic pig kidney can provide prolonged survival (>300 days) using T-cell depletion and chemical immunosuppression. Graft failure was still due to AMR, suggesting that xenoreactive antibodies were still the limiting factor in xenograft survival. 20 Now that there are pigs with a negative cross-match to humans, we wanted to determine whether pig kidneys with xenoantigen reduction and no human complement regulatory transgenes could be transplanted into Rhesus monkeys to achieve prolonged survival using chemical immunosuppression.
We created GGTA1/B4GALNT2 KO pigs and transplanted them into Rhesus monkeys who received T-cell depletion and chemical immunosuppression. We were able to achieve life-sustaining xenograft survival of 435 days in a Rhesus monkey, with 2 other grafts surviving 35 and 100 days. Each xenografted kidney was
DNA Sequencing of Cloned Pigs
DNA sequencing analysis of gRNA/Cas9 targeted GGTA1 and B4GalNT2 regions in the cloned pigs validated knockouts. Genomic DNA from the cloned pig was extracted using GenElute Mammalian Genomic DNA Miniprep Kit (Sigma, St. Louis, MO). Polymerase chain reaction (PCR) was performed with GGTA1 and B4GalNT2-specific primer pairs, respectively. The primers were designed to flank the gRNA/Cas9 target sites and amplified 428 bases GGTA1, and 530 bases of B4GalNT2. Cells with durable homozygous disruptions in all GGTA1 and B4GalNT2 genes were selected.
Preparation and Phenotyping of PBMCs
Whole blood was obtained in acid-citrate-dextrose (ACD) and prepared using Ficoll-Paque Plus (GE Healthcare) to isolate PBMCs. Cells were stained with the lectin isolectin Griffonia simplicifolia, GS-IB4, Alexa Fluor 488 (Molecular Probes, Grand Island, NY) and Dolichos biflorus agglutinin (DBA lectin) labeled with Flourescein (Vector laboratories Burlingame, CA) and compared to cells alone. All cells were suspended at 2 Â 10 6 in Hank's Balanced Salt Solution (HBSS) and incubated for 30 minutes at room temperature with appropriate lectin. Cells were washed with blocking buffer. Flow cytometric analysis was completed on BD Accuri C6 flow cytometer with the C6 Software (BD Biosciences, San Jose, CA).
Tissue H&E and Immunofluorescence Confocal Imaging
Biopsy and nephrectomy specimens were evaluated for pathology using H&E staining and immunofluorescence using confocal microscopy. Frozen tissue sections were fixed using 4% paraformaldehyde for 10 minutes. Fixed sections were blocked with Odyssey blocking buffer (Li-Cor Biosciences) 
Pig-to-rhesus Renal Transplantation
A GGTA1/B4GalNT2 KO pig underwent bilateral nephrectomy on the day of transplantation. Rhesus macaques then underwent bilateral nephrectomies followed by life-sustaining renal transplantation using a GGTA1/B4GalNT2 KO pig kidney. Operations were performed in accordance with Institutional Animal Care and Use Committee regulations. Postoperatively, graft function was monitored with daily urine output assessment and weekly serum chemistries. Quantitative cytomegalovirus (CMV) was measured using a PCR-based assay. Ultrasound-guided biopsies were performed postoperatively.
Treatment Regimen
Recipients underwent T-cell depletion using anti-CD4 and anti-CD8 mAb plus costimulation blockade with anti-CD154, and daily mycophenolic acid and steroids. T-cell depletion began 3 days before transplantation with a 1-time dose of anti-CD4 50 mg/kg IV (cloneCD4R1; NIH Nonhuman Primate Reagent Resource, Boston, MA). Anti-CD8 (clone M-T807R1; NIH Nonhuman Primate Reagent Resource, Boston, MA) was given on postoperative day 0 at 50 mg/kg IV. Anti-CD154 (5c8; NIH Nonhuman Primate Reagent Resource, Boston, MA) was given on days 0, 7, 14, and then biweekly at 20 mg/kg IV. Prophylactic enrofloxacin, fluconazole, and ganciclovir were started on the day of transplant. Fluconazole and enrofloxacin were discontinued when flow cytometry demonstrated sustained T-cell reconstitution. Ganciclovir was continued until CMV titers were negative on 2 consecutive measurements. CMV assays were performed as previously described. 18 Weekly subcutaneous Epogen injections were started for hemoglobin less than 9.5 g/dL and discontinued when hemoglobin reached 12 g/dL.
RESULTS

Production of GGTA1/B4GALNT2 KO pigs
GGTA1 and B4GALNT2 genes are responsible for production of xenoantigens a-gal and Sd a , which are involved in humoral rejection of pig xenografts. Fetal fibroblasts were transfected with plasmids encoding the Cas9 endonuclease and gRNA specific for GGTA1 and B4GALNT2 genes. Fetal fibroblasts that were confirmed to be homozygous for GGTA1 and B4GALNT2 deletions were used in somatic cell nuclear transfer (SCNT). Twenty-eight embryo transfers have resulted in 22 pregnancies for a pregnancy rate of 79%. Thirteen of the 22 pregnancies were carried to term and resulted in 48 total piglets with 40 piglets surviving (83% viability).
The regions encompassing the GGTA1 and B4GALNT2 target sites were evaluated using DNA sequence analysis and also PCR originating at cut site ( Fig. 1A and B ). PBMCs from a single GGTA1/ B4GALNT2 KO pig were subjected to phenotypic analysis, and wild-type pig PBMCs were used as a control. PBMCs of the GGTA1/ B4GALNT2 KO were completely devoid of a-gal or Sd a , whereas the controls were strongly positive for both antigens (Fig. 1C ).
GGTA1/B4GALNT2 KO Pig Kidneys are Devoid of Xenoantigens a-gal and Sd a
To minimize xenoreactive binding to a pig renal xenograft, the GGTA1/B4GALNT2 KO pigs must not express the 2 deleted xenoantigens a-gal and Sd a . Pig kidneys from wild-type and GGTA1/ B4GALNT2 KO pigs were evaluated for expression of xenoantigens a-gal and Sd a using lectin staining and confocal microscopy. Wildtype pig kidneys express a-gal produced by GGTA1, and Sd a produced by B4GALNT2 ubiquitously. The GGTA1/B4GALNT2 KO pig kidney was completely devoid of both a-gal and Sd a (Fig. 1D ).
Rhesus Monkeys Have Reduced Anti-pig PBMC Antibodies to GGTA1/B4GALNT2 KO Compared With GGTA1 KO or GGTA1/CMAH/B4GALNT2 KO PBMCs Rhesus monkeys were cross-matched with PBMC from GGTA1 KO, GGTA1/B4GALNT2 KO, and GGTA1/CMAH/ B4GALNT2 KO PBMCs ( Fig. 2A) . In each monkey, the cross-match revealed less IgM and IgG binding to GGTA1/B4GALNT2 KO than GGTA1 KO, or GGTA1/CMAH/B4GALNT2 KO PBMCs (Fig. 2B) . None of the Rhesus had a negative IgM or IgG flow cross-match (Fig. 3A) , and every Rhesus tested had a CDC-positive cross-match. 
Survival of Recipients of GGTA1/B4GALNT2 KO Pig Kidneys
Because the Rhesus had the best cross-match results with the GGTA1/B4GALNT2 KO pigs, these pigs were used as the kidney donors for this series of 6 transplants (Fig. 3B) . Three recipients rejected their kidneys in the first week post-transplant (5, 6, and 6 days) characterized by elevated creatinine, thrombocytopenia, and severe anemia. One recipient rejected at 35 days, and another rejected at 100 days ( Fig. 4A-E) . The sixth recipient rejected the kidney at 435 days (Figs. 5A-E). None of the 3 long-term survivors experienced significant anemia or thrombocytopenia. Although, all 6 recipients, regardless of outcome, had elevated creatinine and some degree of thrombocytopenia during first week post-transplant (Figs. 4A and B, and 5A and B, and 6A and B).
Pathophysiology of Graft Failure
Pathological analysis of the 3 kidneys that were rejected at 5, 6, and 6 days was similar and revealed interstitial hemorrhage, IgG, IgM, and C4d in the glomeruli. There was little to no cellular infiltrate in the early rejectors (Fig. 6D) . The 2 kidneys rejected at 35 and 100 days had signs of AMR with glomerular plugging and thrombotic microangiopathy (Fig. 4C ). In addition, there was deposition of IgG, IgM, and C4d in the glomeruli ( Fig. 4D and E) . The graft rejected at 435 days had normal biopsy at 170 days, but by day 270, signs of glomerulopathy were preset with thickened glomerular membranes. The rejected explant showed advanced glomerulopathy with weak, diffusely positive IgG, IgM, and C4d staining in the glomeruli (Fig. 5D) . The renal xenograft did not experience significant proteinuria, suggesting that failure to properly filter and reabsorb protein may be due to immunologic failure, not a physiologic incompatibility (Fig. 5E ).
DISCUSSION
Renal transplantation has revolutionized the treatment of ESRD with regards to patient quality and duration of life. The shortage of donor organs has limited the availability of this therapy to patients with ESRD. Xenotransplantation using pig organs could eliminate this shortage, but our inability to combat the AMR that occurs with the transplantation of cross-match positive pig kidneys has prevented progression to the clinic.
The introduction of GGTA1 KO pigs eliminated hyperacute rejection, but baboons immunosuppressed with RATG, tacrolimus, mycophenolate, and steroids were rejected in 6 to 16 days by non-a-gal xenoreactive antibodies. 13 Because there were no known xenoantigens to delete in the pig, investigators added human complement regulatory transgenes and later human thromboregulatory transgenes to combat the impact of AMR. 26 -28 McGregor et al showed that incorporation of the human CD55 transgene eliminated early graft failure and reduced complement activation in cardiac xenografts transplanted into baboons, but failed to prolong graft survival. 28, 29 We used GGTA1 KO/CD55 transgenic pig kidneys transplanted into rhesus monkeys immunosuppressed with immunosuppression either identical or very similar to the regimen used in the monkeys in this manuscript, and found that prolonged survival was dependent upon selecting recipients with low levels of xenoreactive antibodies, and CD4 T-cell depletion. 20 Generally stated, the results from the GGTA1 KO/CD55 transgenic pig kidney transplant series show that recipients with low levels of xenoreactive antibody can achieve prolonged survival with chemical immunosuppression. These results suggest that xenotransplantation could follow the paradigm developed for prolonged survival in allotransplantation, namely the identification of appropriate donor-recipient pairs with histocompatibility testing, followed by appropriate chemical immunosuppression. It should be feasible to use genome editing to delete xenoantigens to create donor pigs to which recipients have no preformed antibodies. The identity of the remaining xenoantigens on the pig cell to which primate antibodies bind is unknown, but is a subject of active investigation in our laboratory.
To develop appropriate donor pigs for transplantation into humans, we used CRISPR/Cas to create triple xenoantigen KO pigs. We deleted enzymes producing a-gal, N-glycolylneuraminic acid, and Sd a antigen to produce the GGTA1/CMAH/B4GALNT2 KO pig. 10 Cross-match results of over 800 patients on the kidney transplant waitlist showed that more than 30% of patients had no detectable xenoreactive antibodies to PBMCs from these new pigs. 22 These new pigs provide the opportunity to test the transplant paradigm of transplanting cross-match negative pig kidneys into patients and then using chemical immunosuppression to achieve prolonged post-transplant survival. 23 The studies described in this manuscript represent the initial attempt to test the paradigm of using histocompatibility testing and chemical immunosuppression in a preclinical pig-to-NHP model. The GGTA1/CMAH/B4GALNT2 KO pig cannot be tested in the rhesus model because the cross-match was significantly worse than the GGTA1/B4GALNT2 KO cross-match. The reasons for this are unclear, but the rhesus has a functional CMAH gene and as such it expresses human xenoantigen Neu5Gc.
The DKO pig kidney had a very improved cross-match when compared with the GGTA1 KO pig, but it was still positive based on the presence of anti-pig IgM. The xenoreactive IgM played a significant role in early graft injury, as each of the recipients experienced significant graft injury at 5 to 6 days post-transplant, manifested by elevated creatinine, thrombocytopenia, and severe anemia. Three of the 6 grafts did not recover, and were rejected early (5-6 days). The other 3 grafts were able to recover and provide more prolonged graft survival, but each of the remaining 3 grafts was eventually lost due to AMR. Our results regarding AMR as the cause of renal xenograft failure are consistent with the findings of our recent experience with long surviving renal xenografts with GGTA1 KO/CD55 transgenic pig kidneys, where all of the grafts were lost to some form of AMR, either early or late. Cooper has also had prolonged renal xenograft survival (8 months in 2 recipients) using GGTA1 KO pigs with multiple human transgenes as donors, but explant pathology showed signs of chronic AMR with significant transplant glomerulopathy, tubular atrophy, and interstitial fibrosis. Taken together, these results suggest that xenoreactive antibodies dominate the pathophysiology of graft failure, and the addition of human complement regulatory, thromboregulatory, or other transgenes fails to alter the pathophysiology of graft failure.
The facts that human transgenes have not altered graft survival or pathophysiology, and that xenoreactive antibodies are still the cause of xenograft failure, have 2 important implications for clinical implementation of xenotransplantation. The first implication is that strict adherence to cross-matching principles where only recipients that have a negative cross-match are considered for initial transplants is likely to be critical to success in achieving prolonged renal xenograft survival in human patients. Starting with no-preformed antibodies in allotransplantation has been a successful strategy for more than 40 years, and now clear guidelines are emerging for preventing early T-cell-mediated rejection that is required for the formation of de novo donor-specific antibodies. 30 De novo donorspecific antibodies in renal allotransplantation are largely directed against class II HLA, [31] [32] [33] and recently we have shown that anti-HLA DQ antibodies cross-react with SLA class II DQ in an epitoperestricted pattern. 34 Given this information, it seems likely that if too little chemical immunosuppression is used in a renal xenograft that the recipient would develop anti-SLA-DQ antibodies. Robust data from the FKC-008 study establish the trough levels of tacrolimus required in conjunction with mycophenolate mofetil, and steroids are required to prevent subclinical T-cell-mediated rejection and severely minimize the development of de novo donor-specific antibody. 35 To improve the survival of pig kidneys transplanted into rhesus monkeys using only antigen deletion, 2 approaches come to mind, the first is to identify other candidate xenoantigens in the donor pig that could be eliminated through genome editing to create a cross-match negative pig with regards to the rhesus monkey. The other option would be to try complement inhibition for the early post-transplant period so that the IgM barrier could be overcome during the critical first few weeks post-transplant. In clinical renal allotransplantation, plasmapheresis with intravenous immunoglobulin (IVIG) is used to desensitize patients, 36, 37 but this will be difficult in xenotransplantation in the human, and also the primate since IVIG contains many xenoreactive antibodies that will attack the xenograft.
Another consideration for implementation of clinical renal xenotransplantation is whether it is necessary to use tacrolimus in an immunosuppressive regimen for the preclinical model rather than anti-CD154 before attempting clinical cases. Currently, there are no rhesus monkeys that have a negative cross-match to the GGTA1/ B4GALNT2 KO pigs, which is not reflective of the situation for the GGTA1/CMAH/B4GALNT2 KO pig and humans. The use of conventional tacrolimus-based allograft immunosuppression has been very successful in renal allotransplantation for cross-match negative transplantation, but far less effective for cross-match positive transplantation. 37, 38 Conventional immunosuppression has been combined with desensitization protocols in clinical allotransplantation, 39, 40 which are not practical for the pig-to-NHP model, especially in light of the fact that the use of IVIG is precluded in xenotransplantation because it will provide a source of additional xenoreactive antibodies and will likely hasten the onset of AMR (personal unpublished observations).
This study is an important landmark for clinical implementation of renal xenotransplantation because it shows that the simplest genome editing approach, namely using xenoantigen deletion alone, can result in prolonged graft survival in a preclinical NHP model. The GGTA1/CMAH/B4GALNT2 KO pig kidney has a negative cross-match negative for many patients and could be used in clinical pilot trials. 22, 23 The use of a xenoantigen reduction strategy without the use of transgenes that interfere with the recipient immune system's ability to interact with the xenograft keeps the protective immunity within the xenograft intact, so that the recipient immune system is able to fight off infection should it occur. This consideration will be particularly important for the initial cases of clinical xenotransplantation, where public safety particularly with regards to zoonotic risk will be a primary concern for all interested parties. [41] [42] [43] The simplistic approach to genome editing for the initial clinical trials will also reduce concerns over evaluating the potential issue of off target effects of genome editing that will come with the use of more complicated genome editing strategies. 44 
DISCUSSANTS
Abraham Shaked (Philadelphia, PA):
In this very interesting presentation, you are describing the use of a fairly sophisticated genetic editing system. The question is how many genes to edit, and whether the 2 xenoantigen determinants that were deleted are good enough to prevent severe xeno immune response. You took these genetically modified kidneys, and you transplant these kidneys in 6 rhesus monkeys. Now, when you look at the results, 3 out of the 6 die within 1 week. Then you have 2 who are relatively short-term survivors and only 1 long-term survivor. All of them, by the end of the day, die from antibody-mediated rejection.
The first question is a very simple one. Is this good outcome or bad outcome? Just listening to your presentation, if I was a nonbiased nephrologist, and a patient of mine was going to come and ask me whether to go into this trial or not, I would be very hesitant to say go forward. Even if you have completely negative cross-matches, and you are waiting 5 years on the list, the risk of failure may not justify enrollment in this study. So this is the first question, is your study outcomes should be considered bad or good?
The second question is related to what else can be done. Between you and me, members of the human species, we probably have about 20 complete loss-of-function genes. Each one of these can produce a protein that can be immunogenic. You probably have data about what is the genetic distance between the pig and the human. Can you predict based on these data, including whole genome sequencing, the potential for significant xeno antibody mediated rejection? Is it possible to determine what other genetic determinants should be knocked out in order to reduce rejection?
The third question is related to actually 2 long-term survivors of the recipients group; these are very interesting survivors. In those, you probably had production of physiologic functioning proteins. Did you notice compatibility or incompatibility with the monkey system. For example, did you observed functioning erythropoietin? What about the renin-angiotensin system, et cetera?
The last question is related to the human candidate that you will be recruiting for your phase I trial; I wonder who are the appropriate recipients? What is going to be the immunosuppression induction and maintenance protocol?
Response From Alfred J. Tector:
Thank you for those questions. In response to your first question, are these results good or bad? I think some of that is going to depend on how people and, particularly, how the regulatory agency looks at this.
Clearly, we want better survival than this, but we do not have a negative cross-match. But I think the comforting thing is we absolutely understand the pathophysiology of graft failure. And if you look at it, it mirrors exactly our transplantation graft failure. So I think if we can get into the paradigm where we have a negative crossmatch, a lot of that will change.
The manuscript that I sent you that I think is coming out in AJT in a little bit where we did Gal knockout with some CD55 transgene, those animals-we got about half a dozen or so out more than a year. We were able to avoid that early injury. Again, because of the complexities of adding transgenes, and some of the theoretical risks about adding complement regulators which put viral receptors for important transplant viruses in the pig and make them a reservoir for new pathogens, we think initially that's going to be a hard process to get through.
But we are also relieved because the path forward is clear. So in May and June, we are going to do a series of experiments. It took us a little while, but we found an US FDA-approved complement inhibitor that is a C-1 inhibitor that is going to be able to get us through that early period in the first 10 days. Because it is an IgMmediated rejection, if we use enough immunosuppression, we do not anticipate a conversion to IgG. That is the first thing.
The second question about the nonfunctional genes is, I think you have gone right to what the issue is. Each of these genes that we have deleted is a gene that you and I have knocked out during the course of evolution. So, really, we are kind of talking about speeding up mammalian evolution.
So we have looked at the pig genes, and we have looked at the human genome. What we went after was unitary pseudogene. That is, single copies of a gene that you and I have deleted. They are nonfunctional, and then we map them to genes that-pigs have functional analogues. Then we eliminated any gene that was not going to get to the cell surface or genes that are locked in organelles that should not be seen by antibody. We came up with 40 genes.
So we have knocked out 40 genes in immortalized renal endothelial cells in this triple knockout background and the double knockout background and screening them with rhesus and baboon, because baboons have the same problem, and then with humans that still have antibodies to the triple knockout. So of those 40 we are down to about 12 that look promising, and we are going to continue to evaluate those a little bit. And then when that comes, we will make a new pig.
As far as physiologic compatibility, I think some of it is going to be hard to test in the primate model. As I am sure you are aware, there are a lot of limitations as to how much manipulation you can do, and getting blood pressures in them is not very easy. I think some of that is just going to have to come out when we try it clinically.
Selection of the patients. We would like to compare this not to allotransplantation, but to not getting a transplant at all. Right now, as we are talking about it at UAB, we are looking at the possibility of taking people that are 60 and older, just getting identified as needing a kidney transplant, who do not have a living donor. In our state, they have between a 5 and 8-year wait. If you are blood group O or B, unlikely to ever get a transplant.
Robert Fisher (Boston, MA):
Joe, I just rise to congratulate you and your team on this longterm effort that is hopefully pushing us to a future with true clinical xenotransplantation.
I have just 1 simple question. If your early graft loss is due to IgM and you now have a 1-pig graft supply that you are going to use for your rhesus population or your human population, is there not a way to determine that particular IgM xenoantigen plasma cell clone that could be eliminated 3 days before the transplantation and then continue B-cell modulation either in your rhesus recipient or your human for this difficulty to be overcome?
Response From Alfred J. Trector:
Thank you for your kind comments. As far as that goes, you are spot on as far as being able to immunomodulate a human recipient. IgM is incredibly easy to Ã pherese off. The issue in the primate is, is when you Ã pherese a primate, it is going to be a lot harder to pull off. And then what do you replace the plasma volume with? If you replace it with more rhesus serum, you are adding more antibody. That is one caveat to doing pheresis and IVIg in humans is you are adding a lot more xeno reactive antibody. So you have to be careful, and we will have to develop those Ã.
But as far as being able to Ã pherese off IgM in a person, I think we are in much better shape to actually transplant a person right now than we are to transplant a primate. I think one of the messages we have is we have now reached the outer limits of what we can get from our preclinical model.
